🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Dolutegravir 50 mg tablet

Found 110 matching trials

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

PHASE2

The goal of this clinical study is to learn more about the effects of switc...

Status

Active Not Recruiting

Location

Be Well Medical Center

Start Date

2022-08-16

Trial ID

NCT05502341

Treatments Being Tested

Bictegravir Lenacapavir BIC/LEN FDC Stable Baseline Regimen

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

PHASE4

The goal of this clinical study is to provide continued access to the study...

Status

Recruiting

Location

Helios Salud

Start Date

2024-08-27

Trial ID

NCT06337032

Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

PHASE1

This is open label, phase 1 clinical study to evaluate the safety, tolerabi...

Status

Completed

Location

Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital"

Start Date

2018-10-01

Trial ID

NCT03706898

Treatments Being Tested

Elpida®Dolutegravir Sofosbuvir Daclatasvir

Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch

PHASE3

Combination antiretroviral therapy (cART) HIV treatments are associated wit...

Status

Recruiting

Location

Mortimer Market Centre

Start Date

2022-08-17

Trial ID

NCT04892654

Treatments Being Tested

Doravirine Dolutegravir Triple cART regimen

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

PHASE1

Dolutegravir (DTG) and lamivudine (3TC) are indicated in combination with o...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-05

Trial ID

NCT02738931

Treatments Being Tested

Dolutegravir 50 mg tablet Lamivudine 300 mg tablet Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

PHASE3

This study will compare safety, efficacy, and tolerability of a two drug re...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-07-18

Trial ID

NCT02831764

Treatments Being Tested

Dolutegravir (DTG)Lamivudine (3TC)Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

PHASE3

First-line antiretroviral regimens are highly efficacious and generally wel...

Status

Completed

Location

GSK Investigational Site

Start Date

2019-05-06

Trial ID

NCT03682848

Treatments Being Tested

DTG + 3TC FDC

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

PHASE3

Dolutegravir is a potent integrase strand transfer inhibitor. Abacavir/dolu...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-06-06

Trial ID

NCT03016533

Treatments Being Tested

Dolutegravir film-coated tablets Dolutegravir film-coated dispersible tablets ABC/DTG/3TC immediate release tablets ABC/DTG/3TC film-coated dispersible tablets

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

PHASE1

Treatment of human immunodeficiency virus (HIV) infection requires daily or...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-02

Trial ID

NCT02373930

Treatments Being Tested

DTG 50 mg RPV 25 mg DTG/RPV 50 mg/25 mg: Product Code AS DTG/RPV 50 mg/25 mg: Product Code AM DTG/RPV 50 mg/25 mg: Product Code AQ DTG/RPV 50 mg/25 mg: Product Code AK DTG/RPV 50 mg/25 mg: Product Code AR

Previous Next